Key causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about:

Similar documents
Cardiovascular Risk Assessment and Management Making a Difference

well-targeted primary prevention of cardiovascular disease: an underused high-value intervention?

Professor Norman Sharpe. Heart Foundation West Coast

HEALTH TARGETS IN PRIMARY CARE

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand

Vascular Diseases. Overview: Selected Slides

Beyond Framingham. Prediction of cardiovascular risk. Niels van Pelt Cardiologist, Middlemore Hospital

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

Coronary Heart Disease in Women Go Red for Women

Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia

Economically efficient approaches to address chronic disease in developing countries

Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf

Current Issues in Cardiovascular Risk Management. Les Toop Norman Sharpe June 2014

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Diabetes Mellitus: A Cardiovascular Disease

Is there a mechanism of interaction between hypertension and dyslipidaemia?

The cost-effectiveness of polypharmacy

Risk Factors for NCDs

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS

Population models of health impact of combination polypharmacy

Ethnic inequalities in mortality: Trends and explanations,

NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell

CVD Prevention, Who to Consider

Heart Age and Cardiovascular Risk

NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell

Socioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women

Associate Professor Gerry Devlin

Cardiovascular Disease Prevention: Current Knowledge, Future Directions

Getting serious about preventing cardiovascular disease

Total risk management of Cardiovascular diseases Nobuhiro Yamada

EuroPrevent 2010 Fatal versus total events in risk assessment models

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Preventive Cardiology Scientific evidence

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

The Clinical Unmet need in the patient with Diabetes and ACS

Absolute cardiovascular disease risk management

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini

Identification of subjects at high risk for cardiovascular disease

The Metabolic Syndrome: Is It A Valid Concept? YES

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants

Dr Chris Ellis. Consultant Cardiologist Auckland

Antihypertensive Trial Design ALLHAT

What s new in cardiovascular disease risk assessment and management for primary care clinicians

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Ischaemic Heart Disease

Management of Hypertension for Stroke Prevention in New Zealand: Can We Do Better? Walter van der Merwe Nephrologist Waitemata DHB

Implementing Type 2 Diabetes Prevention Programmes

Your Name & Phone Number Here! Longevity Index

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

Briefing to the Health Committee Enquiry on the Early Diagnosis and Treatment of Prostate Cancer

Dyslipidemia in women: Who should be treated and how?

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Using the New Hypertension Guidelines

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Volume 2; Number 11 July 2008

Depok-Indonesia STEPS Survey 2003

Guidelines on cardiovascular risk assessment and management

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Medtech Training Guide

Section 3: Health and Independence Report 2013


Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Implementing population based screening programs

Primary Prevention of Stroke

CONTRIBUTING FACTORS FOR STROKE:

Lecture Chronic Non-Communicable Diseases Epidemiology, Risk factors of NCD

Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C

The Health Status of Māori Male Prisoners: Key results from the Prisoner Health Survey 2005

Reducing risk in heart disease

The local healthcare system: Focusing on health

Dr Johan Morreau. Paediatrician Rotorua

Risk Factors for Heart Disease

Using Coronary Artery Calcium Score in the Quest for Cardiac Health. Robert J. Hage, D.O.

Established Risk Factors for Coronary Heart Disease (CHD)

Clinical Audit Tool. Release Notes

10/8/2015. MN Nursing Conference October 7th, 2015 Michael Miedema, MD MPH. None

THE NEW ZEALAND MEDICAL JOURNAL

Corporate Health Screening

THE NEW ZEALAND MEDICAL JOURNAL

The Importance of Local Research in Developing Health Strategy The Case of Cardiovascular Disease Prevention in Sri Lanka

ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009

Blood Pressure Acre Surgery Diviash Thakrar

Chapter 6: Combined Cardiovascular Risk Factors

Primary Care Smoking Cessation. GP and Clinical Director WRPHO Primary Care Advisor MOH Tobacco Team Target Champion Primary Care Tobacco

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Secondary analyses of HSE data and linked health outcomes - an overview of work in progress. UCL (University College London)

CLINICAL PRACTICE EVALUATION I: MEDICAL RECORD REVIEW (Adult Patient Population)

Bridging health promotion intervention policy with behavioral risk factor surveillance in Thailand

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

Heart Disease Genesis

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

major public health burden

We acknowledge the traditional custodians of the land on which we meet today and pay respect to Elders past, present and emerging.

Transcription:

Preventive care - Chronic Disease Management in primary care: a population perspective Rod Jackson University of Auckland New Zealand (22/11/8) Key causes of preventable deaths in New Zealand In a population of 1, New Zealanders, every year there will be about: 1 coronary & stroke deaths 1 diabetic death 1 breast cancer death 1 prostate cancer death 1 suicide every year 1 road traffic death (1 cervical cancer death every 5 years) NZHIS annual mortality statistics Burden of disease in NZ: IHD Stroke CORD Diabetes Depression Asthma Anxiety Lung cancer Road traffic Colorectal ca Dementia Breast ca Suicide/self harm LRTI Osteoarthritis Hearing disorders Prostate ca Substance Burden of dise Due to disease and injury outcome (No. DALYs/1) 1 2 3 4 5 6 7 8 Peripheral arterial Lymphoma/myeloma Martin Tobias MoH 23 Vascular disease management 1

The main causes of CHD & stroke smoking* Burden of disease in NZ: 8 Due to risk factors (No. deaths) 5 1 15 2 25 3 35 4 45 5 Tobacco Cholesterol high blood cholesterol / saturated fat diet* Blood pressure Body mass index Physical inactivity Microbes (infection) Inadequate F&V intake Diabetes high blood pressure* * these 3 factors explain most events in populations Alcohol Violence Other injury hazards Road traffic crashes Radiation (ultraviolet) Sexual behaviours Illicit drug use Martin Tobias MoH 23 4 Smoking prevalence in NZ: 1976-24 P e r c e n t 6 Smoking prevalence in NZ by ethnicity P e r c e n t 35 5 3 % 25 2 4 % 3 15 2 1 5 1976 19811983 19841985 19861987 19881989 1991991 19921993 1994199519961997 19981999 221 222324 Y e a r year 1 M_o r i Pacific peoples European/Other 199 1991 1992 1993 1994 1995 1996 1997 1998 1999 2 21 22 23 24 Y e a r year Blood cholesterol & CHD death CHD PSC. Lancet 27; 37: 1829 39 2

CHD: A. HDL; B. non-hdl; & C. TC/HDL Trends in TC/HDL ratio in Auckland 1982-23 CHD PSC. Lancet 27; 37: 1829 39 Metcalf et al. NZMJ 26 Blood pressure & IHD Type 2 Diabetes is not a disease! 4. Total stroke 4. Total ischaemic heart disease 4. Cardiovascular death Hazard ratio & 95% CI 2. 1. 2. 1. 2. 1..5 4.5 5. 5.5 6. 6.5 7. 7.5.5.5 4.5 5. 5.5 6. 6.5 7. 7.5 4.5 5. 5.5 6. 6.5 7. 7.5 Usual fasting glucose (mmol/l) PSC. Lancet 22; 36: 193 132 Asia Pacific Cohort Studies Collaboration. Diabetes Care 24;27:2836-42 The average NZder is overweight Everyone is getting fatter The optimal BMI Metcalf et al. NZMJ 17 November 26, Vol 119 No 1245. URL: http://www.nzma.org.nz/journal/119-1245/238 Metcalf et al. Auckland studies (unpublished) 3

CHD mortality trends in 35-69 year-old New Zealanders 195-25 www.mortrends.org Stroke mortality trends in 35-69 year-old New Zealanders 195-25 Contribution of changes in risk factors to trends in CHD in New Zealand www.mortrends.org Tobias et al. ANZJPH 28;32: 117-25 Estimated trends in systolic blood pressure by sex, New Zealand: 198-24; standardised for age (35-64 years) Estimated trends in blood cholesterol by sex, New Zealand: 198-24; standardised for age (35-64 years) 4

Estimated trends in tobacco smoking by sex, New Zealand: 198-24; standardised for age (35-64 years) Estimated contribution of risk factor changes to CHD trends by sex, New Zealand: 198-24; standardised for age (35-64 years) 22% 31% 2% 73% 15% 35% 39% 87% Trends in systolic blood pressure in normal, overweight & obese Aucklanders NZ & Japan: CHD mortality 35-69 yrs Metcalf et al. unpublished 28 www.mortrends.org Annual deaths per 5, people 4 35 3 25 2 15 1 Annual deaths from IHD per 5, 5-64 yrs: 195-23 Australia men NZ men 5 195 196 197 198 199 2 Year 5

Please put out that cigarette, grandpa Offer brief advice and NRT to all smokers every time you see them! Ashley Bloomfield MoH 28 Source: Jamrozik K, Dobson A, Tobacco Control, August 1999 Advise all patients to eat less SF Per capita availability of butter 23 Sources of saturated fat in New Zealand diet 1.9 kg/person per yr 3.2 kg/person per yr http://faostat.fao.org/ Eat less salt Aspirin + Statin + BP drugs = > 5% CVD Aspirin Statin ACEI ± Diuretic ± BB ± CCB 6

Benefit of treatment is directly proportional to the pre-treatment risk Difficult to estimate risk in your head Absolute CVD risk by SBP ± other risk factors Usage of CVD risk charts by GPs in NZ: 1999-2; after 6 yrs of risk-based guidelines n= 5 (RR =83%) Never 6% < once per month 39% About once per month 24% > twice per month 31% Jackson et al. Lancet 25. 365:434-4 Arroll. N Z Fam Physician. 22;117:177-183 Percentage on combined BP & lipid lowering medication by 5 year absolute CV risk: 2-3 6 5 % on BP & C medication 4 3 2 1 2 21 22 23 CV 1 history 2% 2 15 3 - <2% 1 4 - <15% 5 5 - <1% <5% 6 Risk 7 not estimable Unpublished data Risk could only be estimated on 1/3 patients Impact of electronic decision support in 1 o care % documented 16% 14% 12% 1% 8% 6% 4% 2% % Documentation of 5yr absolute CVD risk pre Prompt Audit time period post Prompt CVD risk nonmaori CVD risk Maori Wells S et al. Eur J Cardiovasc Prev Rehab 28;15:173-8 7

Framingham predicted versus observed CVD event rates in NZ primary care (35-74 yrs) OBSERVED (Cumulative incidence (%) of CVD event in 5 years (95%CI)) 3 25 2 15 1 5 Framingham Performance: Threshold Discrimination Event rates by risk category 1% 13% 9% 7% 8% 1% 53% 7% 6% Hx CVD 15+% 5% 1-<15% 4% 11% <1% 7% 3% 11% 2% 24% 1% 5 1 15 2 25 3 PREDICTED (Framingham score, 5-year risk, %) Preliminary analyses on PREDICT patient population, personal communication Sue Wells 28 % % of total people (n=44842) % of total events (n=2314) Preliminary analyses on PREDICT patient population, personal communication Sue Wells 28 8